These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17805064)

  • 21. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    Mok TS; Ho S; Chan G; Ho WM; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Lee Y; Lam KC
    J Thorac Oncol; 2007 Sep; 2(9):838-44. PubMed ID: 17805062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
    Crabb SJ; Bradbury J; Nolan L; Selman D; Muthuramalingam SR; Cave J; Johnson PW; Ottensmeier C
    Chemotherapy; 2012; 58(4):257-63. PubMed ID: 22907396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
    Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
    Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
    BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib in small cell lung cancer.
    Soria JC; Johnson BE; Chevalier TL
    Lung Cancer; 2003 Aug; 41 Suppl 1():S49-53. PubMed ID: 12867062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
    Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
    Govindan R; Read W; Faust J; Mc Leod H
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):27-9. PubMed ID: 12886871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
    Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
    J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
    Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH
    J Thorac Oncol; 2007 Sep; 2(9):831-7. PubMed ID: 17805061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
    Natale RB; Socinski M; Sandler A; Israel VP; Miller L
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
    Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
    Sequist LV; Fidias PM; Temel JS; Kolevska T; Rabin MS; Boccia RV; Burris HA; Belt RJ; Huberman MS; Melnyk O; Mills GM; Englund CW; Caldwell DC; Keck JG; Meng L; Jones M; Brown GL; Edelman MJ; Lynch TJ
    J Thorac Oncol; 2009 Nov; 4(11):1389-96. PubMed ID: 19701107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
    Murata Y; Hirose T; Yamaoka T; Shirai T; Okuda K; Sugiyama T; Kusumoto S; Nakashima M; Ohmori T; Adachi M
    Eur J Cancer; 2011 Jun; 47(9):1336-42. PubMed ID: 21458256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
    Huang CH; Williamson SK; Van Veldhuizen PJ; Hsueh CT; Allen A; Tawfik O; Wick J; Smith H; Uypeckcuat AM; Mayo M; Kelly K
    J Thorac Oncol; 2011 Feb; 6(2):372-7. PubMed ID: 21178640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.